Thailand Moves to Update Medical Device Authorization Assessment Rules: What Manufacturers Should Watch

What’s Changing?

Thailand's Food and Drug Administration (Thai FDA) is proposing an update to the rules governing how medical-device authorization applications are assessed.

On 13 August 2026, the Thai FDA's Medical Device Control Division published a draft notification concerning the criteria, procedures and conditions for the assessment of technical documents, testing, establishment inspections, and examinations used when considering authorization of medical devices.

The draft is currently subject to public consultation, with comments open until 10 September 2026.

This means the proposal is not yet a final regulatory requirement. However, it provides an important indication of how Thailand's medical-device authorization framework may continue to develop.

Why Does This Matter?

Medical-device authorization depends on regulators being able to assess whether a product meets applicable requirements for quality, safety and performance.

The proposed update addresses several parts of that assessment process, including:

• Technical document assessment

• Analytical or product testing

• Inspection of establishments

• Other examinations conducted as part of authorization decisions

  
  

For manufacturers preparing to enter Thailand, developments affecting these assessment mechanisms can have practical implications for regulatory planning.

Rather than waiting for a final rule to take effect, companies should monitor the consultation process and assess whether their existing regulatory strategies are prepared for potential changes.

Who Should Pay Attention?

The development is particularly relevant to:

✔ Medical-device manufacturers

✔ International companies planning to enter Thailand

✔ Thai importers and local regulatory representatives

✔ Regulatory affairs teams

✔ Quality and compliance professionals

✔ Companies preparing medical-device authorization applications

It may also be relevant to organizations involved in testing, conformity assessment, or establishment compliance, depending on how the final notification is structured.

What Should Companies Do Now?

1. Monitor the Consultation Process

Because the document is currently a draft, companies should avoid treating the proposed provisions as final requirements.

Instead, regulatory teams should monitor the consultation and any subsequent notification published by the Thai FDA.

2. Review Existing Regulatory Strategies

Companies with upcoming Thai medical-device submissions should review how their applications currently address:

• Technical documentation

• Product testing

• Manufacturing or establishment information

• Supporting evidence for authorization

This can help identify areas that may require attention if the proposed framework is finalized.

3. Maintain Strong Technical Documentation

The proposed focus on technical-document assessment reinforces the importance of maintaining complete and consistent technical documentation.

Manufacturers should ensure that their regulatory files can clearly demonstrate the device's relevant characteristics, intended purpose, safety and performance.

4. Monitor Testing and Inspection Expectations

Companies should also keep track of any changes that could affect testing, inspections or other forms of regulatory examination during the authorization process.

A Second Development Worth Watching

The Thai FDA published another draft on 13 August 2026 concerning the acceptance of ethics committees reviewing human research involving clinical research projects related to medical devices.

This is significant because it shows that Thailand's current regulatory activity is not limited to product authorization alone. The authority is also looking at aspects of the clinical research pathway for medical devices.

Together, these developments suggest continued refinement of Thailand's medical-device regulatory framework.

ARQon Insight

For medical-device companies, regulatory intelligence means monitoring regulatory proposals before they become final requirements.

Thailand's latest consultation is a good example.

The draft does not yet change the requirements that manufacturers must follow today. However, it gives companies an opportunity to understand where the regulatory framework may be heading and prepare accordingly.

For organizations planning market entry, this can be particularly valuable.

Being aware of a regulatory change during consultation is very different from discovering it after implementation.

What This Means for Market Access

Thailand remains an important market for companies seeking to expand their presence in Southeast Asia.

For international medical-device manufacturers, successful market entry requires more than preparing a registration dossier. Companies also need to understand how the regulator approaches:

Technical assessment → Testing → Establishment oversight → Authorization → Post-market compliance

The latest draft demonstrates why regulatory strategies should remain flexible and continuously monitored.

Companies preparing submissions should therefore keep their regulatory intelligence processes active while the Thai FDA consultation is underway.

Key Takeaway

On 13 August 2026, Thailand's Medical Device Control Division published a draft notification proposing updated criteria, procedures and conditions for the assessment of technical documents, testing, establishment inspections and examinations involved in medical-device authorization.

The consultation remains open until 10 September 2026, making this a development that manufacturers and regulatory teams should actively monitor.

Because the proposal is still under consultation, companies should not treat it as a final regulatory requirement yet. Instead, they should monitor the outcome, assess potential implications for their regulatory strategies, and remain prepared to adapt once the final requirements are established.

How ARQon Can Support

ARQon supports healthcare and life-science companies with:

• Regulatory intelligence and monitoring

• Thailand market-entry strategy

• Medical-device registration support

• Regulatory gap analysis

• Technical documentation planning

• Market-access strategy

• Cross-border regulatory planning

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.